X-Ceptor focused on the identification of novel drug candidates that interact with orphan nuclear receptors involved in cholesterol metabolism and cardiovascular disease. Several of its programs were partnered and further developed by large pharmaceutical companies.

Exelixis acquired X-Ceptor in 2004.